Title : Sofosbuvir/velpatasvir and Resistance-associated Substitutions in HCV genotype 3
link : Sofosbuvir/velpatasvir and Resistance-associated Substitutions in HCV genotype 3
Sofosbuvir/velpatasvir and Resistance-associated Substitutions in HCV genotype 3
SOF/VEL and Resistance-associated Substitutions in HCV GT3Alimentary Pharmacology & Therapeutics, June 21, 2018
J. von Felden; J. Vermehren; P. Ingiliz; S. Mauss; T. Lutz; K. G. Simon; H. W. Busch; A. Baumgarten; K. Schewe; D. Hueppe; C. Boesecke; J. K. Rockstroh; M. Daeumer; N. Luebke; J. Timm; J. Schulze zur Wiesch; C. Sarrazin; S. Christensen
Does the presence of resistance-associated substitutions impact the efficacy of therapy with sofosbuvir/velpatasvir with or without ribavirin in patients with HCV genotype 3?
Medscape - Full Text
Abstract and Introduction
Abstract
Background Twelve weeks of the pangenotypic direct–acting antiviral (DAA) combination sofosbuvir/velpatasvir (SOF/VEL) was highly efficient in patients with hepatitis C virus (HCV) genotype 3 (GT3) infection in the ASTRAL–3 approval study. However, presence of resistance–associated substitutions (RASs) in the HCV nonstructural protein 5A (NS5A) was associated with lower treatment response.
Aim To assess the efficacy and safety of SOF/VEL ± ribavirin (RBV) and the impact of NS5A RASs and RBV use on treatment outcome in HCV GT3 infection in a real–world setting.
View Full Article...…..
J. von Felden; J. Vermehren; P. Ingiliz; S. Mauss; T. Lutz; K. G. Simon; H. W. Busch; A. Baumgarten; K. Schewe; D. Hueppe; C. Boesecke; J. K. Rockstroh; M. Daeumer; N. Luebke; J. Timm; J. Schulze zur Wiesch; C. Sarrazin; S. Christensen
Does the presence of resistance-associated substitutions impact the efficacy of therapy with sofosbuvir/velpatasvir with or without ribavirin in patients with HCV genotype 3?
Medscape - Full Text
Abstract and Introduction
Abstract
Background Twelve weeks of the pangenotypic direct–acting antiviral (DAA) combination sofosbuvir/velpatasvir (SOF/VEL) was highly efficient in patients with hepatitis C virus (HCV) genotype 3 (GT3) infection in the ASTRAL–3 approval study. However, presence of resistance–associated substitutions (RASs) in the HCV nonstructural protein 5A (NS5A) was associated with lower treatment response.
Aim To assess the efficacy and safety of SOF/VEL ± ribavirin (RBV) and the impact of NS5A RASs and RBV use on treatment outcome in HCV GT3 infection in a real–world setting.
View Full Article...…..
Free registration may be required.
Thus Article Sofosbuvir/velpatasvir and Resistance-associated Substitutions in HCV genotype 3
That's an article Sofosbuvir/velpatasvir and Resistance-associated Substitutions in HCV genotype 3 This time, hopefully can give benefits to all of you. well, see you in posting other articles.
You are now reading the article Sofosbuvir/velpatasvir and Resistance-associated Substitutions in HCV genotype 3 with the link address https://theleknews.blogspot.com/2018/06/sofosbuvirvelpatasvir-and-resistance.html
0 Response to "Sofosbuvir/velpatasvir and Resistance-associated Substitutions in HCV genotype 3"
Post a Comment